{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PYC.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PYC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PYC.AU\",,,,,undefined,":{"symbol":"PYC.AU","market":"AU","secType":"STK","nameCN":"PYC THERAPEUTICS LTD","latestPrice":1.185,"timestamp":1749622320000,"preClose":1.205,"halted":0,"volume":1815929,"delay":0,"nameEN":"PYC THERAPEUTICS LTD","floatShares":348081085,"shares":583260447,"eps":-0.110129,"marketStatus":"Not Yet Opened","change":-0.02,"latestTime":"06-11 16:12:00 AEST","open":1.205,"high":1.22,"low":1.17,"amount":2178378,"amplitude":0.041494,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.110129,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1749686400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":1.205,"openAndCloseTimeList":[[1749600000000,1749621600000]],"volumeRatio":7.232771306612814,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PYC.AU\",,,,,undefined,":{"symbol":"PYC.AU","floatShares":348081085,"roa":"-58.01%","roe":"-112.79%","lyrEps":-0.095849,"volumeRatio":7.232771306612814,"shares":583260447,"dividePrice":0,"high":1.22,"amplitude":0.041494,"preClose":1.205,"low":1.17,"week52Low":0.9,"pbRate":"12.47","psRate":"27.66","week52High":2.1,"institutionHeld":0,"latestPrice":1.185,"eps":-0.110129,"divideRate":0,"volume":1815929,"delay":0,"ttmEps":-0.110129,"open":1.205,"prevYearClose":1.32,"prevWeekClose":1.2,"prevMonthClose":1.21,"prevQuarterClose":1.22,"fiveDayClose":1.2,"twentyDayClose":1.23,"sixtyDayClose":1.23},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PYC.AU\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PYC.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2542373795","title":"PYC Therapeutics Says Safety Review Committee Approves Dose Escalation in Autosomal Dominant Optic Atrophy Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2542373795","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542373795?lang=en_us&edition=fundamental","pubTime":"2025-06-11 11:23","pubTimestamp":1749612188,"startTime":"0","endTime":"0","summary":"PYC Therapeutics  said that the safety review committee monitoring the single ascending dose study of its drug candidate PYC-001 for patients with autosomal dominant optic atrophy approved an increase in the dose, according to a Wednesday Australian bourse filing.The committee approved an increase in the dose to be administered to patients in groups two and three to 30 micrograms per eye from 10 micrograms, following an evaluation of four-week follow-up data.The study will be followed by a multiple ascending dose study and an open-label extension study, facilitating repeat dosing and the evaluation of the optimal dosing regimen, safety, tolerability, and efficacy profile.The company's shares shed 1% in recent Wednesday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","PYC.AU","BK4539","BK7067","BK4139","LENZ"],"gpt_icon":0},{"id":"2532875698","title":"High Growth Tech Stocks In Australia With Promising Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2532875698","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532875698?lang=en_us&edition=fundamental","pubTime":"2025-05-02 03:35","pubTimestamp":1746128144,"startTime":"0","endTime":"0","summary":"The Australian market has shown resilience with the ASX200 closing up 0.24% at 8,145 points, driven by a notable surge in the IT sector which rose by 4%, highlighting investor confidence in technology stocks amidst mixed performances across other sectors. In this dynamic environment, high growth tech stocks stand out for their potential to capitalize on technological advancements and market trends, making them attractive considerations for investors looking to navigate the evolving landscape.Overview: PYC Therapeutics Limited is an Australian drug-development company focused on discovering and developing novel RNA therapeutics for genetic diseases, with a market cap of A$647.36 million.Assess PYC Therapeutics' past performance with our detailed historical performance reports.Overview: Qoria Limited is engaged in the marketing, distribution, and sale of cyber safety products and services across various regions including Australia, New Zealand, the Un","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/high-growth-tech-stocks-australia-193544104.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["XAO.AU","PYC.AU","BK7024","XKO.AU","WTC.AU","BK7503","XJO.AU","BK7016","QOR.AU","BK7067"],"gpt_icon":0},{"id":"2531998837","title":"ASX Growth Stocks With High Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2531998837","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531998837?lang=en_us&edition=fundamental","pubTime":"2025-04-30 03:38","pubTimestamp":1745955480,"startTime":"0","endTime":"0","summary":"The Australian market has recently shown positive momentum, with the ASX200 closing up 0.92% at 8,070 points, driven by strong performances in sectors like Energy and Utilities. In this environment of growth and sectoral strength, identifying stocks with high insider ownership can be particularly appealing as it often suggests confidence from those who know the company best.Top 10 Growth Companies With High Insider Ownership In Australia. Click here to see the full list of 96 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.Guzman y Gomez Limited's recent sales figures show strong growth, with Q1 2025 network sales reaching A$289.5 million, up from A$234.2 million the previous year. The company has transitioned to profitability, reporting a net income of A$7.3 million for H1 2024-25 compared to a loss previously. Despite substantial insider selling over the past three months, revenue is fore","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/asx-growth-stocks-high-insider-193800414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["DVP.AU","AAL.AU","BK7093","EIQ.AU","BK7129","BK7067","FEX.AU","BK7036","BK7077","BK7096","BK7007","BBT.AU","PYC.AU","ACR.AU","XJO.AU","BK7137","TTT.AU","IMA.AU","NWF.AU","BK7116","BK7016","BK7078","GYG.AU","XAO.AU","CYC.AU","PLT.AU","XKO.AU","BK7508","BK7095"],"gpt_icon":0},{"id":"2529690917","title":"PYC Therapeutics Progresses Objective of Becoming Commercial-Stage Drug Developer; Shares Rise 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529690917","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529690917?lang=en_us&edition=fundamental","pubTime":"2025-04-24 09:39","pubTimestamp":1745458765,"startTime":"0","endTime":"0","summary":"PYC Therapeutics  said it continues to progress towards its 48-month objective of becoming a commercial-stage drug developer under its published operational roadmap, according to a Thursday Australian bourse filing.The focus for the firm now is to generate clinical proof-of-concept for each of its three clinical-stage drug candidates, per the filing.The company will start with the presentation of phase one and two data for its lead blinding eye disease drug candidate in May, the filing said.PYC Therapeutics' shares rose almost 6% in recent trading on Wednesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PYC.AU","BK4139","SSI","BK4007","BK7067","LENZ"],"gpt_icon":0}],"pageSize":4,"totalPage":9,"pageCount":1,"totalSize":36,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PYC.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-11-15","symbol":"PYC.AU","defaultRemindTime":1731625200000,"type":"split","dateTimestamp":1731589200000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"AU","date":"2024-03-18","symbol":"PYC.AU","defaultRemindTime":1710716400000,"type":"split","dateTimestamp":1710680400000,"forFactor":988235,"toFactor":1000000,"ratio":0.988235}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PYC.AU\",market:\"AU\",,,undefined,":[]}}